Mind Medicine (MindMed) Inc. (MNMD)

Market Cap	425.45M
Revenue (ttm)	n/a
Net Income (ttm)	-108.68M
Shares Out	75.37M
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	720,045
Open	5.61
Previous Close	5.77
Day's Range	5.54 - 5.74
52-Week Range	4.70 - 10.44
Beta	2.39
Analysts	Strong Buy
Price Target	25.75 (+356.16%)
Earnings Date	May 7, 2025

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: MNMD
• Website: https://www.mindmed.co

Analyst Forecast

According to 9 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price forecast is $25.75, which is an increase of 356.16% from the latest price.

Price Target

$25.75

(356.16% upside)

Analyst Consensus: Strong Buy